Lack of antileukemic activity of rapamycin in elderly patients with acute myeloid leukemia evolving from a myelodysplastic syndrome

Leukemia Research

Volumn 32, Issue 10, 2008, Pages 1633-1634

  Callera, Fernando ^a   Lopes, Carlos O ^a   Rosa, Evandro S ^a   Mulin, Carla C ^a  

^a Centro de Hematologia do Vale   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; DAUNORUBICIN; RAPAMYCIN;

ACUTE GRANULOCYTIC LEUKEMIA; AGED; ANTINEOPLASTIC ACTIVITY; BLOOD EXAMINATION; CLINICAL ARTICLE; CLINICAL EXAMINATION; DISEASE CLASSIFICATION; DISEASE COURSE; DRUG WITHDRAWAL; FOLLOW UP; HUMAN; LETTER; LOADING DRUG DOSE; MYELODYSPLASTIC SYNDROME; NEUTROPHIL COUNT; PATIENT MONITORING; PERFORMANCE; PRIORITY JOURNAL; REFRACTORY ANEMIA; THROMBOCYTE COUNT; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANTIBIOTICS, ANTINEOPLASTIC; HUMANS; LEUKEMIA, MYELOID, ACUTE; MYELODYSPLASTIC SYNDROMES; SIROLIMUS; TREATMENT FAILURE;

EID: 44749089794     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2008.02.004     Document Type: Letter

References (8)

1. Récher C., Beyne-Rauzy O., Demur C., Chicanne G., Dos Santos C., Mas V.M.-D., et al. Antileukemic activity of rapamycin in acute myeloid leukemia. Blood 105 (2005) 2527-2534
2. Récher C., Dos Santos C., Demur C., and Payrastre B. mTOR, a new therapeutic target in acute myeloid leukemia. Cell Cycle 4 11 (2005) 1540-1549
3. Marx J. Canceŕs perpetual source?. Science 317 (2007) 1029-1031
4. Vardiman J., Harris N., and Brunning R. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 100 7 (2002) 2292-2302
5. Panwalkar A., Verstovsek S., and Giles F.J. Mammalian target of rapamycin inhibition as therapy for hematologic malignancies. Cancer 100 (2004) 657-666
6. Mahalati K., and Kahan B.D. Clinical pharmacokinetics of sirolimus. Clin Pharmacokinet 40 (2001) 573-585
7. Hosoi H., Dilling M.B., and Liu L.N. Studies on the mechanisms of resistance to rapamycin in human cancer cells. Mol Pharmacol 54 (1998) 815-824
8. Huang S., Bjornsti M.A., and Houghton P.J. Rapamycins: mechanism of action and cellular resistance. Cancer Biol Ther (2003) 222-232